Dosing & Uses
Dosage Forms & Strengths
Pharmacologic Stress Agent
Indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress
5 mL (0.4 mg) IVP
Administer as rapid (~10 sec) injection into a peripheral vein using 22 gauge or larger catheter or needle
Inspect visually, prior to admin, DO NOT administer if discolored or particulate matter present
Administer 5 mL saline flush, immediately after
Administer radionuclide myocardial perfusion imaging agent 10-20 sec after saline flush
- Radionuclide may be injected directly into same catheter as regadenoson
No dose adjustment needed in renal impairment including patients end stage renal disease and/or dependent on dialysis
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Rhythm conduction abnormalities (26%)
Chest Discomfort (13%)
Angina or ST segment depression (12%)
Chest pain (7%)
Ventricular conduction abnormalities (6%)
Abdominal discomfort (5%)
Feeling hot (5%)
First-degree AV block (3%)
Anaphylaxis, angioedema, cardiac arrest, respiratory arrest/distress, throat tightness, and urticaria/rashes, atrial fibrillation, seizures, cardiovascular accidents (stroke)
Cardiovascular: Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias including atrial fibrillation with rapid ventricular response (new-onset or recurrent), atrial flutter, heart block (including third-degree block), asystole, marked hypertension, symptomatic hypotension in association with transient ischemic attack, seizures and syncope
Central nervous system: Tremor, seizure, transient ischemic attack, and cerebrovascular accident including intracranial hemorrhage
2/3° AV block or sinus node dysfunction (unless patient has a functioning pacemaker installed)
Appropriate bronchodilator therapy and resuscitative measures should be available prior to and following therapy
1° AV block
QT prolongation has occurred shortly after administration in postmarketing surveillence
Hypotension in association with transient ischemic attack, tremors, syncope, and seizures
Hypertension (transient) may occur following administration
Conduction disturbances; depresses SA and AV node conduction and may produce first, second, and third-degree heart block
Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred
Adenosine receptor agonists may cause dyspnea, bronchoconstriction, and respiratory compromise; caution with asthma or bronchoconstrictive disease
Nucleoside transport inhibitors (eg, dipyridamole) and potentiate the vasoactive effects of regadenoson; withhold for 5 half-lives before regadenoson administration
Methylxanthines (eg, caffeine, theophylline) are adenosine receptor antagonists and inhibit regadenoson’s vasoactive effects; withhold methylxanthines for 5 half-lives before regadenoson administration
Aminophylline may increase risk of seizures associated with regadenoson injection
May lower seizure threshold; new-onset or recurrence of convulsive seizures has occurred following regadenoson injection; some seizures are prolonged and require emergent anticonvulsive management
Hemorrhagic and ischemic cerebrovascular accidents have occurred
New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter reported
Risk for myocardial infarction and death
- Avoid use for cardiac nuclear stress tests in patients with signs or symptoms of acute myocardial ischemia (eg, unstable angina, cardiovascular instability); use may increase risk of fatal MI
- Screen all nuclear stress test candidates for risks
Pregnancy & Lactation
Pregnancy: No available data on therapy use in pregnant women to inform drug-associated risk; in animal reproduction studies, adverse developmental outcomes were observed with therapy administration to pregnant rats and rabbits during organogenesis only at doses that produced maternal toxicity
Lactation: There is no information on presence of regadenoson in human milk, effects on breastfed infant, or effects on milk production; because of potential risk of serious cardiac reactions in breastfed infant, advise nursing mother to pump and discard breast milk for 10 hr after therapy
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Low affinity agonist for the A2A adenosine receptor
Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.